首页> 外文OA文献 >Prognostic impact of matched preoperative plasma and serum VEGF in patients with primary colorectal carcinoma
【2h】

Prognostic impact of matched preoperative plasma and serum VEGF in patients with primary colorectal carcinoma

机译:匹配的术前血浆和血清VEGF对原发性大肠癌患者的预后影响

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In serum, the major part of vascular endothelial growth factor derives from in vitro degranulation of granulocytes and platelets. Therefore, plasma may be preferred for vascular endothelial growth factor measurements. However, which specimen is the best predictor of survival is still debated. The present study analyzed the prognostic value of matched preoperative serum and plasma vascular endothelial growth factor concentrations in patients with colorectal cancer. To establish the reference range among healthy people, vascular endothelial growth factor was analyzed in 50 matched EDTA-plasma and serum samples from healthy blood donors. Preoperatively, in 524 patients with colorectal cancer, matched plasma and serum vascular endothelial growth factor concentrations were analyzed. In the colorectal cancer patients, the median plasma vascular endothelial growth factor concentration (44 pg ml−1) was significantly (P=0.01) higher than the median plasma vascular endothelial growth factor concentration (30 pg ml−1) in the healthy blood donors. In serum, no significant (P=0.30) difference in the median vascular endothelial growth factor concentration was found between colorectal cancer patients (268 pg ml−1) and healthy blood donors (220 pg ml−1). The preoperative vascular endothelial growth factor concentrations were dichotomized by the 95th percentile of the healthy blood donors (plasma=112 pg ml−1, serum=533 pg ml−1). In univariate survival analyses, both high plasma vascular endothelial growth factor (>112 pg ml−1) and high serum vascular endothelial growth factor (>533 pg ml−1) predicted a reduced survival. In multivariate survival analyses, high serum vascular endothelial growth factor (>533 pg ml−1) independently predicted a reduced survival (HR=1.65, P=0.015), while high plasma vascular endothelial growth factor (>112 pg ml−1) did not (HR=1.27, P=0.23). This study indicates that preoperative serum vascular endothelial growth factor apparently is a better predictor of overall survival than the preoperative plasma vascular endothelial growth factor.
机译:在血清中,血管内皮生长因子的主要部分来自粒细胞和血小板的体外脱粒。因此,血浆可优选用于血管内皮生长因子的测量。但是,哪种标本是生存的最佳预测指标仍存在争议。本研究分析了匹配的术前血清和血浆血管内皮生长因子浓度在大肠癌患者中的预后价值。为了确定健康人群的参考范围,在健康献血者的50个匹配的EDTA血浆和血清样本中分析了血管内皮生长因子。术前,对524例大肠癌患者进行了血浆和血清血管内皮生长因子浓度的匹配分析。在大肠癌患者中,健康献血者的血浆血管内皮生长因子浓度中位数(44 pg ml-1)显着(P = 0.01)高于健康献血者中血浆血管内皮生长因子浓度(30 pg ml-1) 。在血清中,在大肠癌患者(268μg/ ml-1)和健康献血者(220μg/ ml-1)之间,未发现中位数血管内皮生长因子浓度存在显着差异(P = 0.30)。术前血管内皮生长因子的浓度按健康献血者的第95个百分位数二等分(血浆= 112μpg·ml-1,血清=533μpg·ml-1)。在单变量生存分析中,高血浆血管内皮生长因子(> 112 pg ml-1)和高血清血管内皮生长因子(> 533 pg ml-1)都预测生存率降低。在多变量生存分析中,高血清血管内皮生长因子(> 533 pg ml-1)独立预测生存率降低(HR = 1.65,P = 0.015),而高血浆血管内皮生长因子(> 112 pg ml-1)否(HR = 1.27,P = 0.23)。这项研究表明,术前血清血管内皮生长因子显然比术前血浆血管内皮生长因子更好地预测了总生存期。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号